SPC
SRPT icon

Silver Point Capital’s Sarepta Therapeutics SRPT Stock Holding History

Silver Point Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-278,278
Closed -$5.36M – 23
2025
Q3 		$5.36M Buy
+278,278
New +$4.96M 0.28% 17

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Silver Point Capital's SRPT Position: Q4 2025 in Review

Silver Point Capital sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 278,278 shares — an estimated $5.36M sold.

Silver Point Capital first reported a position in SRPT in Q3 2025 and held it in 1 quarter. The position peaked at $5.36M in Q3 2025. 344 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Silver Point Capital reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Silver Point Capital sold 278,278 Sarepta Therapeutics shares in Q4 2025, an estimated $5.36M.
  • Silver Point Capital first reported a position in Sarepta Therapeutics in Q3 2025 and held it in 1 quarter.
  • Silver Point Capital's Sarepta Therapeutics position peaked at $5.36M in Q3 2025.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Silver Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.